Advice
following a full submission:
secukinumab (Cosentyx®) is accepted for use within NHS Scotland.
Indication under review: Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.
Secukinumab, compared with placebo, significantly improved symptoms of AS in adults with active disease inadequately controlled with non-steroidal anti-inflammatory drugs.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of secukinumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice190KB (PDF)
Medicine details
- Medicine name:
- secukinumab (Cosentyx)
- SMC ID:
- 1159/16
- Indication:
- Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 July 2016